J. B. Meigs, Epidemiology of cardiovascular complications in type 2 diabetes mellitus, Acta Diabetol, vol.40, issue.2, pp.358-61, 2003.

F. Prattichizzo, L. La-sala, L. Ryden, N. Marx, M. Ferrini et al., Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases, Eur J Prev Cardiol, vol.26, issue.2_suppl, pp.73-80, 2019.

A. B. Goldfine, Assessing the cardiovascular safety of diabetes therapies, N Engl J Med, vol.359, issue.11, pp.1092-1097, 2008.

S. E. Nissen and K. Wolski, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, vol.356, issue.24, pp.2457-71, 2007.

C. H. Hennekens, P. R. Hebert, W. R. Schneider, P. O'brien, D. Demets et al., Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus, Contemp Clin Trials, issue.5, pp.411-414, 2010.

J. J. Holst and C. F. Deacon, Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes, Diabetes, vol.47, issue.11, pp.1663-70, 1998.

W. B. White, C. P. Cannon, S. R. Heller, S. E. Nissen, R. M. Bergenstal et al., Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N Engl J Med, vol.369, issue.14, pp.1327-1362, 2013.

F. Zannad, C. P. Cannon, W. C. Cushman, G. L. Bakris, V. Menon et al., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, vol.2015, issue.9982, pp.2067-76
URL : https://hal.archives-ouvertes.fr/hal-01745763

C. S. Fox, K. Matsushita, M. Woodward, H. J. Bilo, J. Chalmers et al., Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis, Lancet, vol.2012, issue.9854, pp.1662-73

M. Tonelli, P. Muntner, A. Lloyd, B. J. Manns, S. Klarenbach et al., Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study, Lancet, vol.2012, issue.9844, pp.807-821

P. Covington, R. Christopher, M. Davenport, P. Fleck, Q. A. Mekki et al., Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes, Clin Ther, vol.30, issue.3, pp.499-512, 2008.

W. B. White, G. L. Bakris, R. M. Bergenstal, C. P. Cannon, W. C. Cushman et al., EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome, Am Heart J, vol.162, issue.4, pp.620-626, 2011.

A. S. Levey, L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro et al., A new equation to estimate glomerular filtration rate, In Ann Intern Med, United States, vol.150, pp.604-616, 2009.

F. Jp and G. Rj, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, vol.94, pp.496-509, 1999.

R. Christopher and A. Karim, Clinical pharmacology of alogliptin

, inhibitor, for the treatment of Type 2 diabetes, Expert Rev Clin Pharmacol, vol.2, issue.6, pp.589-600, 2009.

Y. Sakai, A. Suzuki, K. Mugishima, Y. Sumi, Y. Otsuka et al., Effects of alogliptin in chronic kidney disease patients with type 2 diabetes, Intern Med, vol.53, issue.3, pp.195-203, 2014.

A. J. Scheen, Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes, Clin Pharmacokinet, vol.54, issue.1, pp.1-21, 2015.

S. N. Baksh, M. Mcadams-demarco, J. B. Segal, and G. C. Alexander, Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients, Pharmacoepidemiol Drug Saf, vol.27, issue.6, pp.660-667, 2018.

J. B. Green, M. A. Bethel, P. W. Armstrong, J. B. Buse, S. S. Engel et al., Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med, vol.373, issue.3, pp.232-274, 2015.

B. M. Scirica, D. L. Bhatt, E. Braunwald, P. G. Steg, J. Davidson et al., Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, vol.369, issue.14, pp.1317-1343, 2013.

J. Rosenstock, S. E. Kahn, O. E. Johansen, B. Zinman, M. A. Espeland et al., Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial, Jama, vol.22, 2019.

J. H. Alexander, M. Pencina, R. D. Toto, C. Wanner, B. Zinman et al., Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial, Jama, vol.2019, issue.1, pp.69-79

S. R. Walker, P. Komenda, S. Khojah, W. Al-tuwaijri, K. Macdonald et al., Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials, Nephron, vol.2017, issue.2, pp.85-94